Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion

References

• YasudaMKiyoharaYArakawaSPrevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama studyInvest Ophthalmol Vis Sci20105163205320920071683
   PubMed Web of Science ®Google Scholar
• WangJKHuangTLSuPYChangPYTsengYYIntravitreal aflibercept for macular edema secondary to branch retinal vein occlusion in Chinese patientsEye Sci2015302636626902063
   PubMedGoogle Scholar
• WangJKSuPYHsuYRChenYJChenFTTsengYYComparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusionJ Ophthalmol20162016842194027190640
   PubMed Web of Science ®Google Scholar
• SaishinYItoYFujikawaMSawadaTOhjiMComparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusionJpn J Ophthalmol Epub2016922
   Web of Science ®Google Scholar
• WirthMABeckerMDGrafNMichelsSAflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab – a pilot studyInt J Retin Vitr2016220
   Google Scholar
• Lehmann-ClarkeLDiraniAMantelIAmbresinAThe effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusionKlin Monbl Augenheilkd2015232455255525902119
   PubMed Web of Science ®Google Scholar
• EadieJAIpMSKulkarniADResponse to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumabRetina201434122439244324999721
   PubMed Web of Science ®Google Scholar
• CohenMNHoustonSKJuhnAEffect of aflibercept on refractory macular edema associated with central retinal vein occlusionCan J Ophthalmol201651534234727769324
   PubMed Web of Science ®Google Scholar
• PfauMFassnacht-RiederleHBeckerMDGrafNMichelsSClinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusionOphthalmic Res201554315015626413794
   PubMed Web of Science ®Google Scholar
• PapakostasTDLimLvan ZylTIntravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumabEye (Lond)2016301798426449196
   PubMed Web of Science ®Google Scholar
• TagamiMKusuharaSImaiHHondaSTsukaharaYNegiAImpact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusionOphthalmologica20112262818621625191
   PubMed Web of Science ®Google Scholar
• CampochiaroPAHeierJSFeinerLRanibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology201011761102111220398941
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPASinghRPRanibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology201011761124113320381871
   PubMed Web of Science ®Google Scholar
• HeierJSCampochiaroPAYauLRanibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trialOphthalmology2012119480280922301066
   PubMed Web of Science ®Google Scholar
• CampochiaroPAClarkWLBoyerDSIntravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT studyOphthalmology2015122353854425315663
   PubMed Web of Science ®Google Scholar
• BoyerDHeierJBrownDMVascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS studyOphthalmology201211951024103222440275
   PubMed Web of Science ®Google Scholar
• HolzFGRoiderJOguraYVEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO studyBr J Ophthalmol201397327828423298885
   PubMed Web of Science ®Google Scholar
• CaponeAJrSingerMADodwellDGEfficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study)Retina201434234235123846381
   PubMed Web of Science ®Google Scholar
• PichiFSpecchiaCVitaleLCombination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusionAm J Ophthalmol2014157360761524528934
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• ParkSJChoiYNaYMIntraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit modelInvest Ophthalmol Vis Sci20165762612261727258433
   PubMed Web of Science ®Google Scholar
• StewartMWWhat are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical modelEye Reports20111e5
   Google Scholar
• StewartMWRosenfeldPJPredicted biological activity of intravitreal VEGF TrapBr J Ophthalmol200892566766818356264
   PubMed Web of Science ®Google Scholar
• FauserSMuetherPSClinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression timesBr J Ophthalmol Epub2016217
   Web of Science ®Google Scholar
• NiwaYKakinokiMSawadaTWangXOhjiMRanibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyesInvest Ophthalmol Vis Sci201556116501650526447985
   PubMed Web of Science ®Google Scholar